Challenges in pancreatic adenocarcinoma surgery - National survey and current practice guidelines
- PMID: 28267771
- PMCID: PMC5340358
- DOI: 10.1371/journal.pone.0173374
Challenges in pancreatic adenocarcinoma surgery - National survey and current practice guidelines
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most deadly cancers in Europe and the USA. There is consensus that radical tumor surgery is the only viable option for any long-term survival in patients with PDAC. So far, limited data are available regarding the routine surgical management of patients with advanced PDAC in the light of surgical guidelines.
Methods: A national survey on perioperative management of patients with PDAC and currently applied criteria on their tumor resectability in German university and community hospitals was carried out.
Results: With a response rate of 81.6% (231/283) a total of 95 (41.1%) participating departments practicing pancreatic surgery in Germany are certified as competence and reference centers for surgical diseases of the pancreas in 2016. More than 95% of them indicate to carry out structured and interdisciplinary therapies along with an interdisciplinary pre- and postoperative tumor board. The majority of survey respondents prefer the pylorus-preserving partial pancreatoduodenectomy (93.1%) with standard lymphadenectomy for cancer of the pancreatic head. Intraoperative histological evaluation of the resection margins is used regularly by 99% of the survey respondents. 98.7% of survey respondents carry out partial or complete vein resection, 126 respondents (54.5%) would resect tumor adjacent arteries, and 102 respondents (44.2%) would perform metastasectomy if complete PDAC resection (R0) is possible.
Conclusion: Evidence-based and standardized pancreatic surgery is practiced by a large number of hospitals in Germany. However, a significant number of survey respondents support an extended radical tumor resection in patients with advanced PDAC even when not indicated by current clinical guidelines.
Conflict of interest statement
Figures
Similar articles
-
Surgical treatment concepts for patients with pancreatic cancer in Germany--results from a national survey conducted among members of the "Chirurgische Arbeitsgemeinschaft Onkologie" (CAO) and the "Arbeitsgemeinschaft Internistische Onkologie" (AIO) of the Germany Cancer Society (DKG).Langenbecks Arch Surg. 2011 Feb;396(2):223-9. doi: 10.1007/s00423-010-0695-1. Epub 2010 Aug 15. Langenbecks Arch Surg. 2011. PMID: 20711737
-
Borderline resectable pancreatic cancer.Cancer Lett. 2016 Jun 1;375(2):231-237. doi: 10.1016/j.canlet.2016.02.039. Epub 2016 Mar 9. Cancer Lett. 2016. PMID: 26970276 Review.
-
White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.Abdom Radiol (NY). 2020 Mar;45(3):716-728. doi: 10.1007/s00261-019-02289-5. Abdom Radiol (NY). 2020. PMID: 31748823 Review.
-
Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent - a multicenter survey in Germany and review of the literature.Z Gastroenterol. 2017 Jul;55(7):657-666. doi: 10.1055/s-0043-105502. Epub 2017 Apr 24. Z Gastroenterol. 2017. PMID: 28437802 Review. English.
-
Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.Abdom Radiol (NY). 2018 Feb;43(2):301-313. doi: 10.1007/s00261-017-1410-2. Abdom Radiol (NY). 2018. PMID: 29198002 Review.
Cited by
-
ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.Mol Oncol. 2019 Feb;13(2):456-479. doi: 10.1002/1878-0261.12426. Epub 2019 Jan 9. Mol Oncol. 2019. PMID: 30556643 Free PMC article.
-
The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.J Cancer Res Clin Oncol. 2018 Dec;144(12):2419-2431. doi: 10.1007/s00432-018-2755-9. Epub 2018 Sep 22. J Cancer Res Clin Oncol. 2018. PMID: 30244390 Free PMC article.
-
Predictive role of radiomics features extracted from preoperative cross-sectional imaging of pancreatic ductal adenocarcinoma in detecting lymph node metastasis: a systemic review and meta-analysis.Abdom Radiol (NY). 2023 Aug;48(8):2570-2584. doi: 10.1007/s00261-023-03940-y. Epub 2023 May 18. Abdom Radiol (NY). 2023. PMID: 37202642
-
Magnesium transporter protein solute carrier family 41 member 1 suppresses human pancreatic ductal adenocarcinoma through magnesium-dependent Akt/mTOR inhibition and bax-associated mitochondrial apoptosis.Aging (Albany NY). 2019 May 8;11(9):2681-2698. doi: 10.18632/aging.101940. Aging (Albany NY). 2019. PMID: 31076559 Free PMC article.
References
-
- Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12(8):1083–93. Epub 2014/08/08. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical